sb1578
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01235871)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
CSF1R inhibitor
FLT3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1- Mol. weight
- 462.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544962 ↗
- ChEMBLCHEMBL2035185 ↗
Also known as
- 15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triazatetracyclo(18.3.1.1(2,5).1(14,18))hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene
- ct-1578
- ct-1578
- sb1578
- sb1578
- sb-1578
- sb-1578
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01235871 | Phase 1 | Aug 1, 2010 | Celerion, S*BIO |
Showing 1 of 1 trials
Page 1 / 1